Lumida
/RVMD
⌘K
Revolution Medicines Inc

Revolution Medicines Inc

RVMD
$203.77USD+0.21%+0.42 today

MARKET CAP

43.7B

P/E (TTM)

FWD P/E

DAY RANGE

$198 – $206

52W RANGE

$42
$224

AI Summary

Stalk
StalkMedium

RVMD remains in a Stage 2 uptrend with no active structural patterns, but price is currently rejecting at the 9- and 20-day EMAs and pulling back into the rising 50-day SMA. We maintain a medium-term bullish bias and will stalk for a firm hold and eventual reclamation of the faster EMAs around the 50-day SMA. A decisive break and close below the 50-day SMA with follow-through selling would invalidate the medium-term bullish bias.

  • FDA approved RASONQUE for metastatic pancreatic cancer with analysts forecasting $11.5B peak sales.
  • Phase 1/2 trials showed 42% confirmed response rate and 16-month median overall survival.
  • Q2 2026 net loss of $644M vs $248M prior year highlights profitability risk.
Full analysis →

Buying

13

institutions

Selling

11

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY13.70 M2.56 B+2.48 M+135.2%0.04%
FC

Farallon Capital Management, L.l.c.

Q2 2026

BUYNEW13.55 M2.54 B+13.55 M+0.0%11.78%
JH

Janus Henderson Group Plc

Q1 2026

BUY19.53 M1.90 B+7.23 M+93.8%0.46%
FC

Farallon Capital Management LLC

Q1 2026

SELL13.60 M1.32 B+-978.00 K+13.9%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY3.30 M636.93 M+3.00 M+2179.5%0.04%
WP

Woodline Partners LP

Q2 2026

SELL2.00 M375.10 M+-3.01 M-23.1%1.16%
AC

Aqr Capital Management LLC

Q2 2026

BUY1.30 M242.61 M+1.18 M+2036.1%0.08%
CA

Citadel Advisors LLC

Q2 2026

BUY1.21 M227.06 M+207.95 K+132.4%0.03%
TR

T. Rowe Price Investment Management, Inc.

Q2 2026

SELL579.38 K108.51 M+-84.67 K+68.0%0.07%
PA

Perceptive Advisors LLC

Q2 2026

BUY527.60 K98.81 M+10.40 K+96.5%1.49%
DF

Duquesne Family Office LLC

Q2 2026

BUY399.59 K74.83 M+83.73 K+143.6%1.44%
CP

California Public Employees Retirement System

Q2 2026

BUY349.93 K65.53 M+67.97 K+139.0%0.04%
MM

Millennium Management LLC

Q2 2026

SELL263.11 K49.27 M+-114.22 K+34.3%0.02%
FA

Fisher Asset Management, LLC

Q2 2026

SELL207.69 K38.90 M+-8.25 K+85.2%0.01%
MG

Man Group Plc

Q2 2026

SELL173.44 K32.48 M+-101.83 K+21.3%0.05%
AC

Adar1 Capital Management, LLC

Q2 2026

SELL87.51 K16.39 M+-46.38 K+25.9%0.76%
MC

Moore Capital Management, LP

Q2 2026

BUY81.70 K15.30 M+26.10 K+183.0%0.23%
PA

Point72 Asset Management, L.P.

Q2 2026

BUY80.58 K15.09 M+77.98 K+5868.1%0.02%
RC

Rockefeller Capital Management L.P.

Q2 2026

BUY14.08 K2.64 M+12.40 K+1513.0%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL9.30 K1.74 M+-114.50 K-85.5%0.00%
EP

Eversept Partners, LP

Q2 2026

BUYNEW6.94 K1.30 M+6.94 K+0.0%0.07%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL4.88 K914.49 K+-11.62 K-43.0%0.01%
VI

Voloridge Investment Management, LLC

Q2 2026

SELL0.000.00+-368.32 K-100.0%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL0.000.00+-6.20 K-100.0%0.00%